HCW Biologics Inc. entered into a $26.25 million development line of credit agreement on April 21, 2023. This five-year, non-amortizing loan, collateralized with real estate assets, provides project financing for the buildout of the Company's new headquarters and manufacturing facility. Funds formerly earmarked for this purpose will be redeployed for clinical development, including multiple Phase 2 clinical trials in cancer indications to continue to evaluate HCW9218, the Company's injectable, bifunctional fusion protein molecule for reduction of senescence; and a Phase 1b clinical study in an autoimmune disease to evaluate HCW9302, the Company's injectability, IL-2-based fusion compound.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | -0.71% | -12.70% | +14.29% |
Apr. 01 | HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 01 | HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.29% | 52.95M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.21% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- HCWB Stock
- News HCW Biologics Inc.
- Hcw Biologics Inc. Secures $26.25 Million Non-Dilutive Financing with Asset-Backed Development Loan